menu search

Biogen shares rise on imminent approval of alzheimer's drug following fda panel vote

Biogen Inc (NASDAQ:BIIB) shares rose in pre-market trading on Monday after a Food and Drug Administration (FDA) panel voted in favor of Eisai and Biog...

June 12, 2023, 8:46 am

Pyxis oncology: a high-stakes gambit in the battle against solid tumors

Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors res...

June 12, 2023, 2:59 am

Usdcad daily analysis – june 12, 2023

The USDCAD currency pair has continued its downward movement, extending from 1.3654 to a recent low of 1.3312. The pair is currently facing a critical...

June 12, 2023, 1:47 am

Usdjpy daily analysis – june 12, 2023

The USDJPY currency pair has been engaged in a period of sideways movement, maintaining a trading range between 138.42 and 140.91. This consolidation ...

June 12, 2023, 1:43 am

Innate pharma to present updated interim phase 2 efficacy results of lacutamab in mycosis fungoides at the international conference on malignant lymphoma

MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced ...

June 12, 2023, 1:00 am

Mid, smallcaps attractive from 5-yr horizon: vinit sambre, head of equities, dsp investment managers

We find ourselves in an intriguing phase of the macroeconomic cycle, where global concerns about a rece...

June 11, 2023, 8:59 pm

Intellia therapeutics announces new positive clinical data from phase 1 study of ntla-2002, an investigational in vivo crispr genome editing treatment for hereditary angioedema (hae)

Extended phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living wi...

June 11, 2023, 12:30 pm

Hudson technologies: certain as refrigerators and air conditioning

Hudson Technologies is a buy due to its low valuation, strong growth, industry leadership, and large total addressable market in the refrigerant whole...

June 11, 2023, 9:11 am

Prophase labs continues to make the right moves - reiterate strong buy

Prophase Labs thrived in the Covid era and then wisely used the gains to invest in new testing capabili...

June 11, 2023, 1:16 am

Ocular therapeutix™ announces 12-month topline data from ongoing u.s.-based phase 1 clinical trial evaluating otx-tki for treatment of wet amd

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI ...

June 10, 2023, 10:30 pm

Nkarta presents nkx019 clinical data at the european hematology association 2023 congress and 17th international conference on malignant lymphoma

7 of 10 r/r NHL patients achieved complete response (70% CR rate) following treatment with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cell...

June 10, 2023, 2:47 pm

Royalty pharma: a strong start to 2023 bodes well for the future

Royalty Pharma acquires royalties on drugs in the commercial phase and the development phase. Thanks to...

June 10, 2023, 11:35 am

Gbpusd weekly analysis – june 10, 2023

The GBPUSD currency pair has been undergoing a consolidation phase, suggesting a temporary pause in the long-term uptrend that originated from 1.0352....

June 10, 2023, 1:29 am

Eurusd weekly analysis – june 10, 2023

The EURUSD currency pair has been trading in a consolidation phase, indicating a pause in the long-term uptrend that originated from 0.9535. The price...

June 10, 2023, 1:25 am

Fda advisory committee votes unanimously to confirm the clinical benefit of leqembi® (lecanemab-irmb) for the treatment of alzheimer’s disease

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory ...

June 9, 2023, 10:45 pm

Allogene therapeutics announces oral presentation of phase 1 data on allo-501/501a in large b cell lymphoma at the international conference on malignant lymphoma (icml) lugano

Long-Term Follow Up Data from phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR...

June 9, 2023, 10:25 pm

Kymera therapeutics announces updated clinical data from the phase 1 trials of stat3 degrader kt-333 and irakimid degrader kt-413

Data shared today in abstracts from the International Conference on Malignant Lymphoma (ICML) Both programs continue to demonstrate substantial target...

June 9, 2023, 10:00 pm

Disc medicine: soaring on epp data release, reality may bite on limited market opportunity

Disc Medicine stock has shown outstanding growth since the company joined the Nasdaq in December last year, gaining nearly 250%. The company released ...

June 9, 2023, 3:32 pm

The top healthcare stocks to buy with $100

Teladoc and Axsome offer solid growth potential and are in the early days of their growth stories. Pfizer offers passive income while investors wait f...

June 9, 2023, 2:00 pm

Disc presents positive initial data from phase 2 beacon trial of bitopertin in patients with erythropoietic protoporphyria (epp) at european hematology association (eha) 2023 congress

Consistent and dose-dependent reductions of protoporphyrin IX (PPIX), the disease-causing metabolite in EPP, were observed in patients treated with bi...

June 9, 2023, 11:00 am


Search within

Pages Search Results: